Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference

17 Maggio 2022

Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®

17 Maggio 2022

United States Ambassador Scott Miller meets the Chairman of Farma Industria Ticino Association

12 Maggio 2022

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

9 Maggio 2022

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)

27 Aprile 2022

FIT premia il miglior lavoro di diploma nella Tecnica dei sistemi chimico-farmaceutica della SSST

29 Marzo 2022

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan

28 Marzo 2022

Febbraio 2022: il settore chimico–farmaceutico spinge le esportazioni a un nuovo un livello record

17 Marzo 2022

“Un ramo industriale in forte crescita” – Intervista a Daniela Bührig, Executive Director di Farma industria Ticino

15 Marzo 2022

Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.

4 Marzo 2022